Blood Screening Market Outlook 2031
The global blood screening market size was valued at USD 2.24 Billion in 2022 and is expected to reach USD 4.19 Billion by 2031, expanding at a CAGR of 7.2% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing blood donations, increase in the incidence of infectious diseases, and government initiatives.
Blood screening involves a process of examining the blood sample to ensure the safety of blood units. Screening donated blood and quarantining of blood or blood components are key steps that is mainly followed during the screening process. They are either released for clinical or manufacturing use or discarded based on the screening findings.
The main purpose of the screening is to detect infection markers in the blood before they are sent for clinical or laboratory use so that any infected blood or blood components are discarded.
The screening tests are widely adopted for examining donated blood to check for numerous infectious diseases such as HBV, HCV, HIV-1, and HIV-2. All blood tests are recorded in laboratories using defined processes and these tests are used to track a variety of diseases, health problems, and other clinical disorders including cancer and infections.
Blood Screening Market Trends, Drivers, Restraints, and Opportunities
- Increasing initiatives by governments and non-governmental organizations for spreading the awareness of blood donation and screening before blood transfusion are projected to boost the market growth during the forecast period.
- Increased adoption rate of screening for hepatitis B, hepatitis C, and HIV viruses is projected to fuel the market growth during the forecast period.
- Affordability and increasing applications of nucleic acid amplification test (NAT) for blood screening are projected to propel the market growth during the forecast period.
- Lack of skilled people and availability of alternative technologies such as digital immunoassay possess as key challenges that can impede the market growth during the forecast period.
- Increasing technological advancement and ongoing R&D programs for developing innovative screening devices are projected to create lucrative opportunities for the market players.
Scope of Blood Screening Market Report
The report on the global blood screening market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Blood Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Reagent and Instrument) and Technology (Nucleic Acid Amplification Test, ELISA, Chemiluminescence Immunoassay & Enzyme Immunoassay, Next-Generation Sequencing, and Western Blotting)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Becton, Dickinson and Company; Thermo Fisher Scientific.; Ortho-Clinical Diagnostics, Inc.; Grifols; Danaher Corporation (Beckman Coulter); Abbott Laboratories; Bio-Rad Laboratories; Inc., F. Hoffmann-La Roche Ltd.; and Siemens Healthineers.
|
Blood Screening Market Segment Insights
Product Segment Analysis
Based on products, the blood screening market is bifurcated into reagent and instrument. The reagent segment is expected to account for a key share of the market during the forecast period owing to its high accuracy and specificity in detecting various elements in very small sample.
Furthermore, reagents are affordable for customers and providing a good return on investment for vendors. On the other hand, the instrument segment is anticipated to expand at a rapid pace during the forecast period due to introduction of several diagnostic devices in the market and rising approval of such instruments.
Technology Segment Analysis
In terms of technology, the market is segmented into nucleic acid amplification test (NAT), ELISA, chemiluminescence immunoassay & enzyme immunoassay, next-generation sequencing, and western blotting.
The NAT segment is expected to constitute a key share of the market during the forecast period owing to its high sensitivity and specificity for viral nucleic acid. The results for nucleic acid from this test are rapid compared to other screening techniques; thus, shortening the window of infection for HBV, HCV, and HIV.
On the other hand, the ELISA segment is anticipated to expand at a rapid pace during the forecast period due to continuous efforts for increasing the specificity, its low cost compared to NAT, increasing demand from Asia Pacific due to rising prevalence of infectious diseases.
Regional Outlook
On the basis of regions, the blood screening market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period.
The regional market growth can be attributed to the existence of major industry players, higher utilization of blood screening processes, rigorous FDA transfusion regulations, and higher patient affordability.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising public awareness about blood donation, increased patient affordability, and a growing emphasis of major industry participants on emerging countries in the region. China, Japan, India, Singapore, and Australia are holding key market shares in the region.
Segments
The global blood screening market has been segmented on the basis of
Products
Technology
- Nucleic Acid Amplification Test (NAT)
- ELISA
- Chemiluminescence Immunoassay (CLIA) & Enzyme Immunoassay (EIA)
- Next-Generation Sequencing (NGS)
- Western Blotting
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the blood screening market are Becton, Dickinson and Company; Thermo Fisher Scientific.; Ortho-Clinical Diagnostics, Inc.; Grifols; Danaher Corporation (Beckman Coulter); Abbott Laboratories; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; and Siemens Healthineers.
Some of these players are widely engaged in main strategies for expanding their market shares and positions by involving in the process of new products development and partnerships or collaborations for business expansion and commercialization of their products.
Request For Customization
Enquiry Before Buying
Speak With Analyst
